Crohn's disease

Search with Google Search with Bing
Information
Disease name
Crohn's disease
Disease ID
DOID:8778
Description
"An intestinal disease that involves inflammation located_in intestine." [url:http\://en.wikipedia.org/wiki/Chron%27s_disease, url:https\://www.genome.gov/Genetic-Disorders/Crohns-Disease]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
NCT ID Status Phase Summary Start date Completion date
NCT05384080 Active, not recruiting A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Poland August 8, 2022 August 31, 2025
NCT03397108 Active, not recruiting Assessing the Drug Exposure Risk of Infants Breastfed by Women With Inflammatory Bowel Disease July 4, 2017 November 30, 2024
NCT03345823 Active, not recruiting Phase 3 A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 March 21, 2018 September 3, 2027
NCT03000101 Active, not recruiting N/A Study of the Role of Pomegranate Juice Ellagitannins in the Modulation of Inflammation in Inflammatory Bowel Disease January 19, 2017 December 29, 2023
NCT05394805 Active, not recruiting A Study of Subcutaneous HUMIRA (Adalimumab) Injection to Assess Adverse Events and Change in Disease Activity In Adult Participants With Moderate to Severe Active Crohn's Disease (CD) June 29, 2022 July 21, 2024
NCT04118088 Active, not recruiting Phase 4 A Study of Darvadstrocel in Adults With Crohn's Disease and Complex Perianal Fistula December 22, 2020 March 31, 2026
NCT02620046 Active, not recruiting Phase 3 A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease April 15, 2016 June 21, 2024
NCT05192863 Active, not recruiting A Study of Vedolizumab in Adults With Crohn's Disease (CD) March 20, 2023 January 12, 2025
NCT03196427 Active, not recruiting Phase 2 Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD) July 30, 2018 November 24, 2025
NCT04809363 Active, not recruiting Phase 4 A Study of CDPATH™ to Help Manage and Treat Crohn's Disease June 25, 2021 June 30, 2026
NCT02412553 Active, not recruiting N/A Dietary Therapy and Gut Microbiome in Crohn's Disease and Ulcerative Colitis October 2014 October 2026
NCT03105102 Active, not recruiting Phase 3 A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease April 9, 2018 May 14, 2026
NCT03000296 Active, not recruiting N/A Autologous Unselected Hematopoietic Stem Cell Transplantation for Refractory Crohn's Disease October 2013 December 2024
NCT06362174 Active, not recruiting Capsule & Omics for pRedicting Exacerbation of Crohn's Disease February 7, 2023 December 31, 2025
NCT03466411 Active, not recruiting Phase 2/Phase 3 A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease April 13, 2018 June 30, 2030
NCT06031038 Active, not recruiting N/A Impact of Telemonitoring in the Management of Complex IBD in Spain: M-TECCU July 1, 2020 April 30, 2024
NCT02130362 Active, not recruiting A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD) August 28, 2014 March 2, 2028
NCT00606346 Active, not recruiting A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease May 31, 2007 June 30, 2038
NCT03559660 Available CUP Certolizumab Pegol (CDP-870) in Adults Suffering From Crohn's Disease (CD)
NCT00078611 Completed Phase 3 A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's Disease March 2004 March 2005
NCT00088062 Completed Phase 1/Phase 2 STA-5326 in Crohn's Disease Patients February 2004 November 2004
NCT00101946 Completed Phase 2 Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease October 2004 July 2006
NCT00105300 Completed Phase 3 Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease October 2004
NCT00106314 Completed Phase 2 An Efficacy and Safety Evaluation of Inflabloc Cap in the Treatment of Patients With Crohn's Disease January 2005 October 2006
NCT00109473 Completed Phase 2 Trial of Growth Hormone Therapy in Pediatric Crohn's Disease April 2005 August 2009
NCT00114465 Completed Phase 4 VSL#3 Versus Placebo in Maintenance of Remission in Crohn's Disease June 2005 December 2008
NCT00114803 Completed N/A Nasal Calcitonin in the Treatment of Bone Mineral Loss in Children and Adolescents With Inflammatory Bowel Disease January 2004 October 2006
NCT00132899 Completed Phase 3 COMMIT (Combination Of Maintenance Methotrexate-Infliximab Trial) December 2005 July 2008
NCT00138840 Completed Phase 2 Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease August 2005
NCT00138879 Completed Citrulline: A Plasmatic Marker to Assess and Monitor Small Bowel Crohn's Disease Patients May 2003 June 2005
NCT00152425 Completed Phase 3 Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo), Following 3 Doses of Active Drug (CDP870). February 2004 May 2005
NCT00152490 Completed Phase 3 A Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo) December 2003 May 2005
NCT00160524 Completed Phase 3 A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] July 2004 August 2012
NCT00160706 Completed Phase 3 A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease February 2004 May 2012
NCT00162942 Completed Phase 3 Study for the Treatment of Crohn's Disease With Adacolumn January 2005 December 2007
NCT00167882 Completed Phase 4 The Influence of 5-Aminosalicylates on Thiopurine Metabolite Levels July 2005 August 2006
NCT00175292 Completed Phase 3 A Randomized Controlled Trial of VSL#3 for the Prevention of Endoscopic Recurrence Following Surgery for Crohn's Disease. December 2003
NCT00195715 Completed Phase 3 Long-term Safety and Tolerability Study of Adalimumab in Subjects With Crohn's Disease September 2004 December 2008
NCT00215020 Completed Evaluation of Urinary Isoprostanes in the Assessment of Children With Inflammatory Bowel Disease September 2003 June 2006
NCT00221026 Completed Phase 2 Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Crohn's Disease December 2004 June 2006
NCT00222378 Completed Prevalence of Cytomegalovirus, Epstein Barr Virus and Human Herpes 6 Virus in Inflammatory Bowel Disease April 2005 June 2012
NCT00225810 Completed Phase 4 A Study Comparing the Acceptability of Pentasa® Sachets Versus Pentasa® Tablets in Children With Crohn´s Disease October 2005 February 2006
NCT00234741 Completed Phase 2 Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease November 2005
NCT00237055 Completed Infectious Agents in Pediatric Crohn's August 2004 September 2006
NCT00245947 Completed Phase 1 Study Evaluating ERB-041 in Active Crohn's Disease April 2004 April 2005
NCT00250198 Completed Phase 2 The Immunological and Blood Effects of STA-5326 Mesylate on Patients With Crohn's Disease November 3, 2005 September 5, 2006
NCT00267709 Completed Phase 2 Visilizumab for Treatment of Perianal Fistulas in Crohn's Disease February 2005 December 2006
NCT00267722 Completed Phase 2 Visilizumab for Moderate to Severe Inflammatory, Nonstricturing, Nonpenetrating Crohn's Disease February 2005 December 2006
NCT00269386 Completed Phase 3 Clarithromycin in Active Crohn's Disease April 2000 May 2007
NCT00274209 Completed Chromoendoscopy for Ulcerative Colitis Surveillance December 2005 November 2011
NCT00280956 Completed Phase 4 Open Label Natalizumab Safety Extension Study for Subjects With Crohn's Disease July 2002 September 2004
NCT00287170 Completed Phase 1/Phase 2 Efficacy Study of Targeted, Local Delivery of Drugs to Treat Crohn's Disease July 2006 December 2007
NCT00289328 Completed Glucocorticoid-induced Osteopenia in Children November 2001 April 2006
NCT00291668 Completed Phase 2 Clinical Study of CDP870/Certolizumab Pegol in Patients With Active Crohn's Disease March 2, 2006 November 8, 2007
NCT00294112 Completed Phase 2 Prochymal™ Adult Human Mesenchymal Stem Cells for Treatment of Moderate-to-severe Crohn's Disease March 13, 2006 July 21, 2006
NCT00297648 Completed Phase 3 Mucosal Healing Study in Crohn's Disease (CD) February 2006 December 2009
NCT00300118 Completed Phase 3 Oral Budesonide vs. Oral Mesalazine in Active Crohn's Disease (CD) September 2004 May 2008
NCT00305409 Completed N/A Synbiotic Treatment in Crohn's Disease Patients June 2006 December 2008
NCT00306215 Completed Phase 2 A Study to Evaluate the Efficacy and Safety of CCX282-B in Subjects With Moderate to Severe Crohn's Disease March 2006 June 2009
NCT00308438 Completed Phase 2 Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease Who Completed Protocol CL0600-008 March 1, 2004 June 1, 2006
NCT00308581 Completed Phase 3 Certolizumab in Crohn's Disease Patients With Loss of Response or Intolerance to Infliximab April 2006 April 2008
NCT00329420 Completed Phase 2 Maintenance Study Including Re-induction Therapy for Patients Who Did Not Show a Clinical Effect in Study C87037 (NCT00291668) May 2006 May 2008
NCT00329550 Completed Phase 2 Maintenance Study of Certolizumab Pegol (CZP) in Crohn's Disease May 2006 April 2008
NCT00333788 Completed Phase 3 Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease October 2006 April 2010
NCT00338650 Completed Phase 3 Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE) June 2006 May 2007
NCT00343642 Completed Phase 1/Phase 2 Dietary Treatment of Crohn's Disease September 2006 October 2012
NCT00348283 Completed Phase 3 Effects of Adalimumab on Mucosal Healing in Subjects With Crohn's Disease Involving the Colon August 2006
NCT00356408 Completed Phase 3 Examining the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Crohn's Disease January 2007 February 2010
NCT02826330 Completed Abnormal Fecal Microbiota in Healthy Subjects at High Risk for Crohn's Disease October 3, 2013 April 3, 2019
NCT00004941 Completed Phase 3 Phase III Randomized Study of Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody (cA2) for Patients With Enterocutaneous Fistulae as a Complication of Crohn's Disease July 1996 July 1996
NCT00007163 Completed Phase 1 Monoclonal Antibody Treatment of Crohn's Disease December 2000 November 2002
NCT00025805 Completed Phase 1 G-CSF to Treat Crohn's Disease October 23, 2001 June 13, 2008
NCT00032786 Completed Phase 3 Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease March 2002 March 2004
NCT00032799 Completed Phase 3 Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease December 2001 September 2003
NCT00035503 Completed Phase 2 Multicenter Trial For Patients With Acute Crohn's Disease January 31, 2002 January 31, 2004
NCT00042055 Completed Phase 2 CP-461 for the Treatment of Crohn's Disease July 2002 September 2003
NCT00048113 Completed Phase 3 Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease January 10, 2001 April 27, 2002
NCT00048295 Completed Phase 3 Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease May 2002
NCT00055367 Completed Phase 2 Safety, Tolerability and Effectiveness of Natalizumab in Adolescents With Active Crohn's Disease April 2002 May 2004
NCT00055497 Completed Phase 3 Remission in Subjects With Crohn's Disease, 1 Year Phase August 2002 December 2008
NCT00055523 Completed Phase 2 A Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease April 2002
NCT00055536 Completed Phase 2 Safety and Efficacy of Natalizumab in Combination With Remicade in the Treatment of Crohn's Disease April 2002 July 2003
NCT00061737 Completed Quality of Life in Pediatric Inflammatory Bowel Disease January 2003
NCT00072839 Completed Phase 2 Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease November 12, 2003 July 28, 2005
NCT00072943 Completed Phase 2 A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn's Disease March 2002 April 2004
NCT00074542 Completed Phase 3 An Efficacy and Safety Study of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's Disease September 2002 January 2005
NCT00077779 Completed Phase 3 Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease July 2003
NCT00818272 Completed Remicade Safety Line (Crohn's Disease)(Study P03288)(COMPLETED) December 2002 December 2010
NCT00819663 Completed Intestinal Wall Remodeling (Infliximab Therapy) in Crohn's Disease Patients Undergoing Serial Computed Tomography (CT) Enterography February 2009 August 2010
NCT00838149 Completed Phase 1 Effect of Glutamine on Intestinal Permeability in Crohn's Disease November 2005 November 2008
NCT00844285 Completed SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry January 30, 2009 August 21, 2020
NCT00889161 Completed Phase 1 Curcumin in Pediatric Inflammatory Bowel Disease May 2009 June 2010
NCT00917514 Completed An Investigational Study to Test Usability of the Electronic Dosing Equipment Medicpen June 2009 February 2010
NCT00944736 Completed Phase 3 Effect of VSL#3 on Intestinal Permeability in Pediatric Crohn's Disease July 2009 July 2013
NCT00946946 Completed Phase 3 Preventing Postoperative Relapse in Crohn's Disease Patients at Risk: Azathioprine Versus Mesalazine February 2002 July 2009
NCT00950105 Completed Phase 1 Single Ascending Dose Study of Oral CPSI-2364 (Semapimod) July 2009 October 2009
NCT00988832 Completed An Audit of Patients With Crohn's Disease Treated With Infliximab (P06066) February 2010 December 2010
NCT00989560 Completed Phase 3 Post-operative Crohn's Endoscopic Recurrence Study August 2009 April 2013
NCT00989573 Completed Phase 2/Phase 3 A Dose-finding and Confirmatory Trial of OPC-6535 in Patients With Active Crohn's Disease October 2009 August 2012
NCT01019460 Completed N/A A Comparative Study of Capsule Endoscopy, Magnetic Resonance Imaging and Computer Tomography Scanning of the Small Bowel in Crohn's Disease October 2007 August 2011
NCT01030809 Completed Phase 4 Trial of a Treatment Algorithm for the Management of Crohn's Disease January 2010 December 2013
NCT01032525 Completed Monroe County Inflammatory Bowel Disease (IBD) Registry January 1981 March 2014
NCT01037322 Completed Phase 1/Phase 2 Cannabidiol for Inflammatory Bowel Disease January 2010 September 2012
NCT01051622 Completed Phase 1 PBMC (Peripheral Blood Mononuclear Cells) /Lymphocyte SPECT (Single Photon Emission Computerized Tomography) Imaging in Crohn's Disease January 2010 February 2011
NCT01053559 Completed N/A Assessment of Small Bowel Healing in Crohn's Disease Patients Treated With Cimzia Using Wireless Capsule Endoscopy January 2010 September 2013
NCT01070303 Completed Phase 3 Remission in Subjects With Crohn's Disease, Open Label Extension August 2002 December 2008
NCT01083121 Completed Surveillance of Humira Injection in Korean Patients April 2007 June 2012
NCT01083680 Completed Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine May 2007 December 2015
NCT01086059 Completed OTIS Autoimmune Diseases in Pregnancy Project November 2003 October 2019
NCT01105741 Completed Metabolomic Analysis, a Potential Tool to Direct Treatment With Adalimumab in Crohn's Disease (CD) June 2010 December 2013
NCT01114607 Completed Phase 1 A Study to Assess the Relative Bioavailability of Four New Formulations of GSK1605786 in Healthy Subjects May 5, 2010 June 29, 2010
NCT01144962 Completed Phase 1/Phase 2 Dose-escalating Therapeutic Study of Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for the Treatment of Fistulas in Patients With Refractory Perianal Crohn's Disease June 2010 December 2014
NCT01155362 Completed Phase 2 A Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease August 2010 April 2014
NCT01181765 Completed Phase 4 The Efficacy of Open Label Infliximab for the Induction and Maintenance of Mucosal Healing in Small Bowel Crohn's Disease Assessed Through Wireless Camera Endoscopy June 2012 January 2013
NCT01183403 Completed CE-U and MRE to Predict the Efficacy of Anti-TNF Therapy in Crohn's Disease January 2010 July 2012
NCT01190410 Completed Phase 2 Extension Study to Assess Long Term Safety in Children and Adolescents With Crohn's Disease Receiving Certolizumab Pegol August 2010 November 27, 2017
NCT01203631 Completed Phase 2 Safety and Efficacy of NNC 0142-0000-0002 in Subjects With Moderately to Severely Active Crohn's Disease February 2011 May 2013
NCT01215890 Completed Phase 4 Risedronate Therapy in the Treatment of Low Bone Mineral Density in Crohn's Disease
NCT01224171 Completed Phase 3 Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease November 2010 April 2012
NCT01233960 Completed Phase 3 Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease November 29, 2010 September 15, 2014
NCT01235325 Completed Phase 4 The Effect of Vitamin K Supplementation on Bone Health in Adult Crohn's Disease Patients July 2008 November 2010
NCT01235689 Completed Phase 3 Efficacy and Safety of Two Treatment Algorithms in Adults With Moderate to Severe Crohn's Disease February 11, 2011 January 3, 2017
NCT01258205 Completed Phase 1 Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects February 28, 2011 February 18, 2015
NCT01261286 Completed Phase 1 Drug-Disease Interaction in Crohn's Disease
NCT01275508 Completed Phase 1/Phase 2 Safety and Tolerability of FITC-Adalimumab Administration During Confocal Laser Endomicroscopy of the Gut January 2011 April 2012
NCT01276509 Completed Phase 2 Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease April 6, 2011 October 9, 2015
NCT01277666 Completed Phase 3 A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease December 20, 2010 July 11, 2013
NCT01287897 Completed Phase 2 A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy February 2011 February 2015
NCT01290042 Completed Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181. February 2011 May 2014
NCT01291810 Completed Phase 2 Clinical Efficacy of TNFa Kinoid in Crohn's Disease Patients February 2011 May 2014
NCT01296841 Completed Phase 2 Telemedicine To Provide Inflammatory Bowel Disease Outpatient Care October 2009 June 2010
NCT01297907 Completed Bronchial Hyperreactivity in Children With Crohn Disease May 2008 December 2009
NCT01298492 Completed Phase 2 A Study To Monitor Long-Term Treatment With PF-00547659 July 1, 2011 July 27, 2016
NCT01298648 Completed Special Investigation in Patients With Crohn's Disease (All Patients Investigation) November 2010 February 2013
NCT01314079 Completed Follow-up Study of Autologous Cultured Adipose-derived Stem Cells for the Crohn's Fistula April 2010 August 2012
NCT01316601 Completed Phase 2 A Study to Assess Efficacy, Safety and Tolerability of the Anti-IL-13 Monoclonal Antibody QAX576 in the Treatment of Perinanal Fistulas in Patients Suffering From Crohn's Disease January 2011 November 2012
NCT01338740 Completed Switching From Adalimumab to Infliximab April 2011 February 17, 2014
NCT01341808 Completed Phase 4 Immunogenicity of Hepatitis A Vaccine in Inflammatory Bowel Disease (IBD) Patients April 2011 March 2013
NCT01345318 Completed Phase 2 B0151005 Open-Label Extension Study June 2011 March 2016
NCT01345799 Completed Phase 2 A Study of TRK-170 for the Treatment of Crohn's Disease April 2011 April 2014
NCT01346826 Completed Phase 4 Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease (IBD) May 2011 April 2016
NCT01349504 Completed Adherence to Mesalamine Profile for Patients With Inflammatory Bowel Disease April 2011 December 2012
NCT01352221 Completed Phase 3 Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Crohn's Disease (AEGIS-2) August 2011 October 2014
NCT01355614 Completed Phase 2 A Phase II Efficacy Study in Fistulizing Crohn's Disease Patients June 2011 March 2013
NCT01363427 Completed Retrospective Data Analysis in Crohn's Disease March 2007 July 2010
NCT01369329 Completed Phase 3 A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1) July 2011 July 2013
NCT01369342 Completed Phase 3 A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2) July 2011 October 2014
NCT01369355 Completed Phase 3 A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI) September 13, 2011 October 1, 2019
NCT01369667 Completed Phase 4 Vitamin D Supplementation in Adult Crohn's Disease April 2012 May 2015
NCT01372969 Completed Phase 1/Phase 2 Study to Assess the Safety and Efficacy of Expanded Allogenic Adipose-derived Stem Cells (eASCs) (Cx601), for Treatment of Complex Perianal Fistulas in Perianal Crohn's Disease. June 2009 September 2010
NCT01387594 Completed Phase 1 Evaluate PF-00547659 On Cerebrospinal Fluid Lymphocytes In Volunteers With Crohn's Disease Or Ulcerative Colitis Who Failed Or Did Not Tolerate Anti-TNFs May 3, 2012 November 26, 2015
NCT01392365 Completed Development of a Prediction Model for Differential Diagnosis Between Intestinal Tuberculosis and Crohn's Disease July 2011 February 2015
NCT01393626 Completed Phase 2 A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease October 2011 March 2015
NCT01393899 Completed Phase 2 The Safety And Efficacy Of Maintenance Therapy With CP-690,550 March 2012 July 2015
NCT01405105 Completed Exacerbating Factors in Inflammatory Bowel Disease August 2009 June 2012
NCT01417728 Completed Endomicroscopy in IBD Patients May 2011 August 2013
NCT01434693 Completed Phase 1 Safety and Tolerability of Single Doses Oral CNDO 201 Trichuris Suis Ova in Patients With Crohn's Disease November 2011 September 2012
NCT01442025 Completed Phase 4 Study Investigating Tailored Treatment With Infliximab for Active Crohn's Disease June 2012 July 2015
NCT01444092 Completed Phase 3 Safety Study of Entocort for Children With Crohn's Disease November 2011 September 2014
NCT01453946 Completed Phase 3 Safety and Maintenance Study of Entocort for Children With Crohn's Disease December 2011 February 2014
NCT01464333 Completed Special Investigation (Long-term Investigation) in Patients With Crohn's Disease December 16, 2011 March 31, 2018
NCT01466374 Completed Phase 2 Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease December 2011 December 2014
NCT01468090 Completed Disease Course in an IBD Cohort in the Era of Biological Treatment October 2011 June 2014
NCT01470599 Completed Phase 2 A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease April 2012 July 2016
NCT01476995 Completed Prognostic Indicators as Provided by the EPIC ClearView September 2010 June 2011
NCT01489943 Completed Phase 1 A Study to Investigate the Effect of GSK1605786 on Hepatic Cytochrome P450, and BCRP and OATP1B1 Transport in Healthy Adult Subjects September 19, 2011 November 10, 2011
NCT01496053 Completed Phase 2/Phase 3 Anti-inflammatory Effect of Agaricus Blazei Murill in Inflammatory Bowel Disease (IBD) December 2011 January 2016
NCT01505855 Completed Phase 4 Efficacy Study of Pneumococcal Vaccination in Crohn's Disease December 2011 June 2013
NCT01514240 Completed Phase 3 Phase III Study of D9421-C 9 mg in Patients With Active Crohn's Disease in Japan February 2012 September 2014
NCT01517516 Completed Multi Modal Imaging: An MRI Study to Investigate Differences in the Structure and the Function of the Brain at Rest. March 2011 July 2015
NCT01536509 Completed N/A Improving Medication Adherence in Pediatric Inflammatory Bowel Disease February 2012 May 31, 2016
NCT01540942 Completed N/A Impact of Disease Activity and Nutrition Treat on Postoperative Recurrence and Complications After Bowel Resection for Crohn's Disease November 2011 December 2013
NCT01541579 Completed Phase 3 Adipose Derived Mesenchymal Stem Cells for Induction of Remission in Perianal Fistulizing Crohn's Disease July 2012 November 2016
NCT01545063 Completed CAre of Patients With PArenteral Nutrition At Home May 2012 April 2013
NCT01556672 Completed Phase 4 Adalimumab-psoriasis and Small Bowel Lesions April 2012 April 2016
NCT01560377 Completed Phase 1 Perfusion Assessment in Laparoscopic Left Anterior Resection May 2012 November 2013
NCT01573078 Completed Psychology of Crohn's Disease May 2012 January 28, 2015
NCT01576120 Completed Phase 1/Phase 2 Evaluation of a PillCam Colon Bowel Preparation Regimen in Crohn's Disease Patients March 2012 July 2014
NCT01576471 Completed Phase 2 Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo July 2012 October 2014
NCT01596894 Completed Phase 4 Azithromycin Based Therapy for Induction of Remission in Active Pediatric Crohn's Disease October 2012 December 2015
NCT01611805 Completed Phase 1 Japanese Phase I of GSK1605786 July 22, 2010 October 6, 2010
NCT01631435 Completed Phase 1/Phase 2 PillCam® Platform With the PillCam Crohn's Disease Capsule June 2012 February 2014
NCT01659762 Completed Phase 1 A Phase I Study Evaluating Autologous Bone Marrow Derived Mesenchymal Stromal for Crohn's Disease. July 2012
NCT01661257 Completed Phase 3 Expression of TIM-3 and Correlation With Disease Activity in Pediatric Crohn's Disease With Anti TNF-α Therapy October 2009 June 2011
NCT01663142 Completed Early Postoperative Recurrence in Crohn's Disease: Predictors of Research Targeting the Constitutional Mutation of IRGM October 2010 December 2017
NCT01666626 Completed Ultrasound Stiffness Imaging in Crohn's Disease September 2012 July 2015
NCT01676324 Completed FOCUS: The Future of Fecal Calprotectin Utility Study for the Diagnosis and Management of Inflammatory Bowel Disease (IBD) September 2012 September 2013
NCT01692743 Completed Phase 3 Telemedicine in Patients With Inflammatory Bowel Disease (TELE-IBD) September 2012 September 2016
NCT01692808 Completed Phase 2 Bioavailability of Vitamin D in Children and Adolescents With Crohn's Disease October 2012 November 2014
NCT01696396 Completed Phase 2 Abrilumab (AMG 181) in Adults With Moderate to Severe Crohn's Disease December 4, 2012 April 10, 2018
NCT01696838 Completed N/A Efficacy of Acupuncture and Moxibustion Treatment in Patients With Quiescent Crohn's Disease:Evaluation With fMRI September 2012 November 2014
NCT01697761 Completed N/A Efficacy of Acupuncture and Moxibustion Treatment in Patients With Active Crohn's Disease September 2012 November 2014
NCT01698307 Completed Phase 4 Enhanced Algorithm for Crohn's Treatment Incorporating Early Combination Therapy March 28, 2014 April 16, 2020
NCT01698970 Completed N/A Effect of the Consumption of a Probiotic Strain on the Prevention of Post-operative Recurrence in Crohn's Disease February 2004 March 2010
NCT01714726 Completed Phase 2 Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease. February 1, 2013 December 14, 2016
NCT01720368 Completed OPERA Database - Crohn's Protocol October 2012 June 2015
NCT01728870 Completed N/A Partial Enteral Nutrition With a Unique Diet vs. Exclusive Enteral Nutrition for the Treatment of Pediatric Crohn's Disease January 2013 July 2018
NCT01736046 Completed Comparison of Standard and Low Dose CT Enterography for Crohn's Disease December 2012 March 2015
NCT01749813 Completed Specific Carbohydrate Diet as Maintenance Therapy in Crohn's Disease April 2012 May 2015
NCT01751152 Completed Phase 2 A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease February 2013 December 2014
NCT01757964 Completed Phase 1 Bacteriotherapy in Pediatric Inflammatory Bowel Disease December 2012 January 2015
NCT01759264 Completed An Observational Study of Fecal Calprotectin as Clinical Tool in Monitoring Moderate-to-severe Crohn's Disease on Adalimumab Induction Therapy: a KoRean Experience (FAIR) January 2013 May 2014
NCT01783106 Completed Phase 2 Antibiotics and Hydroxychloroquine in Crohn's February 1, 2014 September 30, 2019
NCT01792388 Completed Phase 4 Vitd and Barrier Function in IBD December 2011 March 2012
NCT01793376 Completed Development of Niv Score of Capsule Endoscopy in Patients With Crohn's (CECDAIic) February 2013 June 2016
NCT01809275 Completed Phase 1/Phase 2 Safety and Treatment Effect of QBECO in Moderate to Severe Crohn's Disease March 2013 July 2016
NCT01813500 Completed Host Immune Response to Clostridium Difficile Infection in Inflammatory Bowel Disease Patients October 2011 April 2016
NCT01823029 Completed N/A Oxidative Stress and Inflammation Caused by Intravenous Iron in Crohn's Disease Patients With Iron Deficiency Anemia November 2012 November 2013
NCT01826188 Completed Phase 1/Phase 2 Combined THC and CBD Drops for Treatment of Crohn's Disease March 2013 June 2018
NCT01827631 Completed Phase 1 Single and Repeat Dose Pharmacokinetic Study of GSK1605786 in Healthy Chinese Subjects May 27, 2013 June 25, 2013
NCT01828190 Completed N/A The Influence of Hyperbaric Oxygen in Patients With Perianal Crohn's Disease Already Treated With TNF Alpha Blockers Treated With TNF Alpha Blockers March 2013 July 2015
NCT01847170 Completed Phase 1 Impact of Fecal Biotherapy (FBT) on Microbial Diversity in Patients With Moderate to Severe Inflammatory Bowel Disease May 2013 November 2016
NCT01860846 Completed Anti-Tumor Necrosis Factor (TNF) Treatments, Work Productivity and Quality of Life in Crohn's Disease May 2013 February 2016
NCT01881490 Completed N/A The ImageKids Study: Developing the pMEDIC and the PICMI January 2013 March 2017
NCT01891214 Completed Validation of the French Version of the Inflammatory Bowel Disease Questionnaire (IBDQ) for Ulcerative Colitis and Crohn's Disease December 2013 January 2017
NCT01916161 Completed The Influence of Information Sources on Knowledge and Anxiety in Inflammatory Bowel Disease Patients October 2013 February 2016
NCT01926730 Completed N/A Food and Crohn's Exacerbation Study (FACES) November 2013 June 2016
NCT01931644 Completed At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions July 2013 April 2024
NCT01951326 Completed Phase 3 Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease September 2013 August 2019
NCT01957423 Completed N/A Immune Response Regulation and Nutritional Status of the Crohn's Disease Patients. March 2012 March 2013
NCT01958827 Completed Phase 3 A Study of Adalimumab After Dose Escalation in Japanese Subjects With Crohn's Disease September 2013 October 2015
NCT01959087 Completed N/A Single Port Colic Laparoscopic Surgery January 27, 2014 March 24, 2017
NCT01966744 Completed Self-Management Assistance for Recommended Treatment (SMART) Portal July 2013 June 2016
NCT01988506 Completed Phase 2 Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases January 6, 2014 April 1, 2021
NCT01991314 Completed Phase 4 Treatment of Iron Deficiency Anaemia in Inflammatory Bowel Disease With Ferrous Sulphate December 2011 June 2015
NCT02010762 Completed Phase 4 The Effect of Vitamin D3 to Maintain Surgical Remission in Postoperative Crohn's Disease February 2013 December 2017
NCT02015793 Completed Phase 2 Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Two Treatment Modules in Chinese Subjects With Moderate to Severe Crohn's Disease December 2013 February 2015
NCT02019602 Completed Phase 1 A Multicener, Postmarketing Study Evaluating the Transfer of Cimzia From the Mother to the Infant Via the Placenta January 2014 November 2016
NCT02038920 Completed Phase 3 Phase III Study of MLN0002 (300 mg) in Treatment of Crohn's Disease January 28, 2014 May 21, 2019
NCT02039063 Completed Phase 1/Phase 2 A Phase 1/2 Study of Repeated Intravenous E6011 Administration in Japanese Subjects With Crohn's Disease April 5, 2014 November 27, 2017
NCT02048618 Completed Phase 2 Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease February 2014 February 2016
NCT02054533 Completed Study to Determine Risk Factors for Post-operative Infection in Inflammatory Bowel Disease February 2014 June 30, 2017
NCT02057016 Completed Long-term Scheduled Therapy With Infliximab in Inflammatory Bowel Disease February 2014 December 2014
NCT02065089 Completed N/A Development of 'Emma'--a Pediatric IBD Quiz February 6, 2014 January 5, 2017
NCT02065570 Completed Phase 3 Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease May 1, 2014 January 30, 2020
NCT02073526 Completed Anti-TNF-alpha Trough Level Measurements in Inflammatory Bowel Disease May 2013 November 2016
NCT02084290 Completed N/A Evaluating a Shared Decision Making Program for Crohn's Disease March 2014 December 31, 2018
NCT02096861 Completed Phase 3 Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 in Patients With Active Crohn's Disease September 19, 2014 February 15, 2017
NCT02097797 Completed N/A Impact of the Fecal Flora Transplantation on Crohn's Disease May 2014 August 30, 2017
NCT02108938 Completed Brain-Gut Interactions in Crohn's Disease September 10, 2014 May 18, 2015
NCT02148185 Completed Phase 1 Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety Study of MT-1303 in Subjects With Crohn's Disease May 2014 June 2014
NCT02148640 Completed Phase 4 The NOR-SWITCH Study October 2014 January 2017
NCT02154425 Completed Phase 1 A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers September 2014 January 2016
NCT02177071 Completed Phase 4 A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy October 9, 2015 October 2021
NCT02179372 Completed N/A Eicosapentaenoic Free Fatty Acid and Fecal Calprotectin in Inflammatory Bowel Diseases June 2014 November 2016
NCT02185014 Completed Phase 3 Open Label Study to Evaluate Long Term Efficacy, Safety and Tolerability of Repeated Dosing in Subjects With Crohn's Disease and Who Participated and Successfully Completed M14-115 August 12, 2014 November 3, 2017
NCT02185183 Completed Phase 1/Phase 2 Oral Administration of AlequelTM for Patients With Inflammatory Bowel Disease (IBD) January 2008 January 2010
NCT02186275 Completed Phase 3 The Vitamin D in Pediatric Crohn's Disease February 2016 December 20, 2019
NCT02193048 Completed Prospective Evaluation of a Scoring System in Patients Newly Diagnosed With Crohn's Disease September 2014 December 31, 2021
NCT02197780 Completed Head-to-head Comparison of Two Fecal Biomarkers to Screen Children for IBD September 2014 April 2017
NCT02199561 Completed Phase 1/Phase 2 Fecal Microbiota Transplantation (FMT) in the Management of Active Crohn's Disease July 2014 December 2016
NCT02201693 Completed N/A Cyclic Exclusive Enteral Nutrition as Maintenance Therapy for Pediatric Crohn's Disease December 12, 2014 October 2, 2019
NCT02213835 Completed N/A Treatment With the Specific Carbohydrate Diet for Children With Active Crohns Disease and Ulcerative Colitis June 2014 September 2017
NCT02231814 Completed N/A The Crohn's Disease Exclusion Diet With Partial Enteral Nutrition or Alone in Adult Patients With Crohn's Disease December 2016 December 2020
NCT02233062 Completed N/A Impact of Exclusive Enteral Nutrition Therapy on Sperm Quality of Patients With Crohn's Disease May 2013 August 2014
NCT02255370 Completed Phase 3 Curcumin Associated With Thiopurin in the Prevention of Post-op Recurrence in Crohn Disease December 2014 June 2018
NCT02256462 Completed Phase 4 Pediatric Crohn's Disease AdalImumab Level-based Optimization Treatment (PAILOT) Trial May 1, 2015 January 31, 2019
NCT02265588 Completed N/A Healthy Approach to Physical and Psychological Problems in Youngsters With IBD (HAPPY-IBD). September 2014 August 24, 2017
NCT02269358 Completed Phase 4 Salvage Therapy With High/Low Methotrexate for Loss of Response to Infliximab Dose Escalation July 2015 October 9, 2018
NCT02274714 Completed Dysmenorrhea in Women With Crohn's Disease and Ulcerative Colitis May 2010 January 2017
NCT02316678 Completed Patient Attitudes and Preferences for Outcomes of Inflammatory Bowel Disease Therapeutics September 2014 December 2016
NCT02319798 Completed N/A Telephone Consultation as a Substitute for Routine Out-patient Face-to-face Consultation for Children With Inflammatory Bowel Disease July 2010 January 2014
NCT02322008 Completed Anti-TNF Therapy in Danish Patients With Inflammatory Bowel Diseases in Clinical Practice September 2009 March 2011
NCT02322307 Completed N/A Trial on Impact of HealthPROMISE Mobile App on Inflammatory Bowel Disease Care and Quality of Life February 2015 January 20, 2020
NCT02365649 Completed Phase 2 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy March 17, 2015 August 3, 2017
NCT02378688 Completed Phase 2 Safety and Efficacy of MT-1303 in Subjects With Moderate to Severe Active Crohn's Disease March 2015 October 2016
NCT02379117 Completed Eating Behaviour in Crohn's Disease April 2015 January 2018
NCT02389790 Completed Phase 2 Extension Study of MT-1303 in Subjects With Crohn's Disease August 2015 August 2017
NCT02423460 Completed N/A Threonine Requirement in IBD Adults and Healthy Adult Controls May 2015 September 23, 2018
NCT02423512 Completed The Impact of Anti-TNF Exposure on Vedolizumab Effectiveness June 2015 June 13, 2017
NCT02425111 Completed Phase 3 Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease March 30, 2015 February 21, 2018
NCT02426567 Completed N/A The Impact of "Crohn's Disease-TReatment-with-EATing" Diet and Exclusive Enteral Nutrition on Healthy Gut Bacteria November 2014 July 2015
NCT02451839 Completed An ObserVatIonal STudy of the Effectiveness of AdaLimumab on Health and Disability Outcomes in New Zealand Patients With Immune-Mediated InflammaTorY Diseases (VITALITY) July 6, 2015 December 5, 2017
NCT02466217 Completed Phenomics in Autoimmune and Inflammatory Diseases July 29, 2015 July 18, 2022
NCT02488005 Completed N/A The Use of Small Bowel Ultrasound to Predict Response to Remicade Induction April 2016 August 17, 2017
NCT02499783 Completed Phase 3 Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's Disease August 17, 2015 December 15, 2017
NCT02501291 Completed Phase 2 Thalidomide in Treating Crohn's Disease January 2013 April 2015
NCT02502552 Completed Study of Anti-glycan Antibodies Stability in Saint-Etienne IBD Cohort November 2013 October 2015
NCT02508012 Completed N/A Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases September 24, 2015 January 1, 2020
NCT02517684 Completed Phase 4 Top-down Infliximab Study in Kids With Crohn's Disease April 2015 January 2024
NCT02531113 Completed Phase 2 Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease October 9, 2015 November 28, 2019
NCT02538341 Completed Phase 2 Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial) May 2016 December 2020
NCT02538679 Completed N/A A Comparison of Ultrasound Guided Transversus Abdominis Plane Nerve Block Techniques August 7, 2015 April 30, 2017
NCT02539368 Completed Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Inflammatory Bowel Disease April 22, 2015 October 31, 2018
NCT02542917 Completed Home Versus Postal Testing for Faecal Calprotectin: a Feasibility Study September 2015 August 2016
NCT02549976 Completed N/A Evaluation of Digestive Damage and Associated Predictive Factors in Crohn's Disease 5 to 10 Years After Diagnosis December 2015 February 2018
NCT02550158 Completed N/A A Study Evaluating the Impact of an Educational Program (EDU-MICI) on Patients With Inflammatory Bowel Disease June 2011 April 2015
NCT02559037 Completed N/A Acupuncture Treatment for Active Crohn's Disease April 1, 2015 November 30, 2019
NCT02559713 Completed Phase 4 Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Active Ulcerative Colitis or Crohn's Disease November 29, 2017 February 22, 2019
NCT02580864 Completed Bologna IBD Markers October 2015 January 2019
NCT02610101 Completed N/A Nutritional Therapy Study in Pediatric Crohn's Disease November 2015 December 2018
NCT02611817 Completed Phase 3 Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease (CD) January 4, 2016 August 6, 2019
NCT02615288 Completed N/A High Dose Vitamin D3 in Crohn's Disease January 2014
NCT02619552 Completed Impact of Medical Treatment on Sexual Function in Patients With Crohn's Disease August 2011 July 1, 2019
NCT02620514 Completed N/A Medication Adherence in Patients With Inflammatory Bowel Disease (IBD) June 2015 November 1, 2016
NCT02622139 Completed N/A Multispectral Optoacoustic Tomography (MSOT) for the Evaluation of Disease Activity in Inflammatory Bowel Diseases (IBD) November 2015 December 2019
NCT02624414 Completed N/A Capsule Colonoscopy in Crohn's Disease and Its Correlation With Conventional Colonoscopy and Faecal Calprotectin February 6, 2015 May 5, 2022
NCT02630966 Completed Phase 4 Vedolizumab IV 300 mg in the Treatment of Fistulizing Crohn's Disease August 10, 2016 November 14, 2018
NCT02678052 Completed OTIS Vedolizumab Pregnancy Exposure Registry December 1, 2015 July 31, 2022
NCT02680756 Completed Phase 3 Safety and Efficacy Study of Oral Ferric Maltol Compared to Intravenous Iron To Treat Iron Deficiency Anaemia in IBD January 2016 January 2019
NCT02704728 Completed N/A Study of Bacteroides Thetaiotaomicron in Young People Aged 16 to 18 Years With Stable Crohn's Disease December 2015 April 2018
NCT02709694 Completed Imaging Biomarkers in Crohn's Associated Spondyloarthritis April 2016 January 2021
NCT02735941 Completed Study on Cannabinoid Receptor Expression in Gastrointestinal Diseases June 13, 2017 July 27, 2018
NCT02742597 Completed N/A Patient-Centred Innovations for Persons With Multimorbidity - Ontario January 12, 2016 October 19, 2022
NCT02742714 Completed N/A PillCam SBC System Functionality in Established and Suspected IBD Patients July 2016 March 2017
NCT02745457 Completed Body Composition in Children With Inflammatory Bowel Disease April 2016 July 31, 2023
NCT02749630 Completed Phase 1 A Safety Study of Intravenously Administered UTTR1147A in Healthy Volunteers (HVs), Participants With Ulcerative Colitis (UC), and Participants With Crohn's Disease (CD) April 11, 2016 February 19, 2020
NCT02750800 Completed Post-marketing Observational Study to Evaluate the Incremental Impact of AbbVie's Patient Support Program on Patient Reported Outcomes and Health Resource Utilization in Inflammatory Arthritis, Psoriasis and Inflammatory Bowel Diseases in Hungary (VALUE) April 7, 2016 April 3, 2018
NCT02765256 Completed Phase 2 Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease August 2016 December 2018
NCT02772458 Completed N/A Reduced Appetite in Crohn's Disease: The Role of the Brain in the Control of Food Intake June 2015 September 2018
NCT02789800 Completed N/A Patient-Centred Innovations for Persons With Multimorbidity - Quebec April 22, 2016 November 1, 2022
NCT02801240 Completed N/A Effect of a Comprehensive Nutrition Support Product on the Nutritional Status of Adults With Inflammatory Bowel Disease June 1, 2016 December 16, 2016
NCT00004423 Completed N/A Controlled Trial of 4-Aminosalicylic Acid in Patients With Small Bowel Crohn's Disease December 1995 March 1998
NCT02843100 Completed N/A Diet for Induction and Maintenance of Remission and Re-biosis in Crohn's Disease April 10, 2018 May 29, 2022
NCT02846961 Completed Anti CT-P13 Antibody in Moderate to Severe Inflammatory Bowel Disease July 2016 December 2020
NCT02847884 Completed IDeaL Pilot Study - Infliximab Dose to Level: Pilot Study October 2015 June 2018
NCT02859675 Completed Olfactogustatory Perception, Eating Behaviour and Inflammation in Crohn's Disease October 7, 2013 May 3, 2021
NCT02862132 Completed N/A Predicting Response to Vedolizumab in Pediatric Inflammatory Bowel Diseases January 2017 January 2022
NCT02883296 Completed N/A Long-term Follow-up of Anal Fistulae in Crohn's Disease Treated With Anti-TNFalpha and Interest of New MRI Sequences April 2011 June 2014
NCT02883452 Completed Phase 1 A Phase I Study to Evaluate Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous in Patients With Active Crohn's Disease and Ulcerative Colitis September 29, 2016 October 2, 2019
NCT02891226 Completed Phase 2 A Study of Mirikizumab (LY3074828) in Participants With Active Crohn's Disease December 14, 2016 February 5, 2021
NCT02896985 Completed Observational Study Evaluating the Effectiveness of Drug Concentration to Predict the Recapture of Response in Crohn's Disease Patients With Loss of Response ( PRADA ) December 16, 2016 March 11, 2020
NCT02914561 Completed Phase 3 Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease October 31, 2016 November 11, 2022
NCT02942511 Completed Predictors Favoring the Role of Exclusive Enteral Nutrition in Active Crohn's Disease January 1, 2014 December 30, 2017
NCT02943538 Completed N/A Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU) May 2014 December 2016
NCT02965209 Completed N/A European Novel Motorized Spiral Endoscopy Trial November 2015 February 6, 2018
NCT02976129 Completed Phase 2 A Six Week Efficacy, Safety and Tolerability Study of V565 in Crohn's Disease December 2016 March 8, 2019
NCT02994836 Completed Phase 4 GIS-SUSANTI-TNF-2015 (Anti-TNF Discontinuation ) April 21, 2017 December 31, 2022
NCT02998398 Completed Evaluation of the Switch From the Original Infliximab to Its Biosimilar in Daily Practice at Cochin Hospital October 2015 June 29, 2016
NCT03010787 Completed Phase 1 A First Time in Human Study in Healthy Volunteers and Patients September 2015 March 2016
NCT03104413 Completed Phase 3 A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment December 18, 2017 May 19, 2021
NCT03105128 Completed Phase 3 A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease May 10, 2017 April 14, 2021
NCT03138655 Completed Phase 2 Vedolizumab IV in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD) November 8, 2017 May 26, 2020
NCT03155945 Completed Phase 2 Tolerability, Pharmacokinetics, and Efficacy of APD371 in Participants With Crohn's Disease Experiencing Abdominal Pain July 19, 2017 September 10, 2018
NCT03223012 Completed Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Axial Spondyloarthritis, in the Portuguese National Health Service November 15, 2017 February 28, 2019
NCT03234907 Completed Phase 3 Vedolizumab Intravenous (IV) Compared to Placebo in Chinese Participants With Crohn's Disease. August 3, 2017 August 14, 2020
NCT03279081 Completed Phase 3 Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Participants With Crohn's Disease (CD) September 15, 2017 July 26, 2023
NCT03283085 Completed Phase 3 A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA) February 27, 2018 December 13, 2023
NCT03338894 Completed N/A A Trial of Yoga in Pediatric Inflammatory Bowel Disease December 13, 2017 December 31, 2021
NCT03345836 Completed Phase 3 A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy November 29, 2017 August 11, 2021
NCT03345849 Completed Phase 3 A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies December 7, 2017 January 13, 2022
NCT03395184 Completed Phase 2 Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease February 2, 2018 October 19, 2023
NCT03404557 Completed Proteomic Analysis of Crohn's Disease Macrophages in Response or Not to AIEC January 18, 2018 January 18, 2019
NCT03662919 Completed One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort Study July 2, 2018 June 30, 2022
NCT03677648 Completed Phase 2 A Phase II Study in Patients With Moderate to Severe Active Crohn's Disease May 14, 2019 December 9, 2021
NCT03733314 Completed Phase 2 A Study of E6011 in Participants With Active Crohn's Disease April 25, 2019 April 3, 2024
NCT03757065 Completed Cell Surface Marker Expression in Autoimmune Diseases June 12, 2019 October 25, 2019
NCT03854305 Completed Phase 2 Phase 2a Study of PRV-6527 in Subjects With Moderately to Severely Active Crohn's Disease March 20, 2018 August 13, 2019
NCT03871634 Completed Assessment of Nutritional Status of Patients With Crohn's Disease December 18, 2018 August 31, 2023
NCT03884439 Completed Infliximab Biosimilar "Pfizer" Drug Use Investigation (Crohn's Disease or Ulcerative Colitis) March 18, 2019 February 2, 2024
NCT03926130 Completed Phase 3 A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease July 23, 2019 October 2, 2023
NCT03945019 Completed Phase 3 CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Crohn's Disease (LIBERTY-CD) October 28, 2019 August 22, 2023
NCT04075825 Completed Phase 3 Long-term Follow-up Study With Darvadstrocel in the Treatment of Complex Perianal Fistula November 4, 2019 April 2, 2024
NCT04131504 Completed Precision Crohn's Disease Management Utilizing Predictive Protein Panels (ENvISION) October 16, 2019 October 31, 2023
NCT04163016 Completed Phase 1 A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol) June 19, 2020 May 23, 2023
NCT04254783 Completed Phase 1 A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease May 27, 2020 October 14, 2022
NCT04297566 Completed MICISPORT Survey : Questionnaire February 20, 2020 June 30, 2020
NCT04538638 Completed N/A Mesenteric SParIng Versus Central mesenterectomY in Ileocolic Resection for Terminal Ileitis in Crohn's Disease March 1, 2020 November 27, 2023
NCT04650867 Completed Non Invasive Characterization of Pediatric Inflammatory Bowel Diseases Using Multispectral Optoacoustic Tomography March 22, 2021 December 20, 2022
NCT04852666 Completed Comparative Effectiveness of Biologics or Small Molecule Therapies in Inflammatory Bowel Disease (IBD) July 25, 2019 December 15, 2022
NCT04956991 Completed CT Diagnoses in Crohn"s Disease Activity June 1, 2011 December 30, 2017
NCT05034458 Completed N/A Diet in Pediatric Crohn´s Disease Treated With Biologics May 14, 2021 June 20, 2023
NCT05088369 Completed Phase 1 Assessment of the Safety, Tolerability, and Pharmacokinetic of HM201 November 11, 2021 December 19, 2022
NCT05242458 Completed A Study of Ustekinumab Treatment in Children With Crohn's Disease March 21, 2022 May 22, 2023
NCT05363930 Completed N/A The MOTOR-CD Trial May 7, 2022 September 30, 2022
NCT05596422 Completed A Study of Vedolizumab and Biologic Agents in Participants With Inflammatory Bowel Disease (IBD) May 27, 2021 December 8, 2022
NCT05815355 Completed Efficacy of Exclusive Enteral Nutrition in Adult Active Crohn's Disease July 2013 September 2015
NCT05867784 Completed Effect of Vitamin D Supplementation on the Efficacy of Ustekinumab in the Treatment of Crohn's Disease April 30, 2021 March 15, 2023
NCT06126146 Completed An Observational Study to Assess Participant-Reported Real-World Experience of Risankizumab On-body Injector (OBI) for the Treatment of Crohn's Disease in Adult Participants in the United Kingdom (UK) October 26, 2023 May 16, 2024
NCT06299631 Completed Endoscopic Relapse Risks Evaluation After Ileocolic Resection for Crohn's Disease January 2015 December 2023
NCT00374374 Completed N/A Treatment With Lactobacillus Rhamnosus and Lactobacillus Acidophilus for Patients With Active Colonic Crohn's Disease. May 2001 November 2005
NCT00409617 Completed Phase 3 Study of Adalimumab Treatment for Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease December 2006 July 2008
NCT00409682 Completed Phase 3 Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease April 2007 May 2010
NCT00417391 Completed Phase 2 Phase II Study of RR110 in Patients With Active Crohn's Disease December 2006 May 2008
NCT00427804 Completed N/A Tumor Necrosis Factor Decreases Vitamin D Dependant Calcium Absorption January 2007 November 2009
NCT00427921 Completed Phase 3 Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects With Moderate to Severe Crohn's Disease (ACCESS) January 2007 January 2008
NCT00445432 Completed Phase 2/Phase 3 A Study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects With Crohn's Disease March 2007 November 2010
NCT00445939 Completed Phase 2/Phase 3 A Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects With Crohn's Disease February 2007
NCT00446433 Completed Phase 2 A Study to Evaluate CC-5013 in the Treatment of Adolescents and Adults With Moderately Severe Crohn's Disease March 2002 December 2003
NCT00462072 Completed Phase 4 Centocor Microarray Study of Patients March 2007 August 2010
NCT00467922 Completed Phase 3 An Assessment of Goal-Directed Intraoperative Fluid Management in Hand Assisted Laparoscopic Colectomy May 2007 October 2009
NCT00472992 Completed Pregnancy Exposure Registry for Tysabri® January 2007 July 2012
NCT00482092 Completed Phase 3 Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease September 17, 2007 September 15, 2014
NCT00487396 Completed N/A Evaluation of Capsule Endoscopy in Patients With Suspected Crohn's Disease September 2007 November 2010
NCT00492791 Completed Endoscopic Severity Score of Small Bowel Crohn's Disease With Wireless Capsule Endoscopy March 2007 December 2011
NCT00496548 Completed N/A Urinary Prostaglandin E Metabolite (PGE-M), A Metabolite of Prostaglandin E2 (PGE2): A Novel Biomarker of Crohn's Disease Activity August 2007 December 2015
NCT00509639 Completed Phase 3 Evaluation of Topical 10% Metronidazole Ointment for the Treatment of Active Perianal Crohn's Disease May 2005 February 2008
NCT00516776 Completed The Innate Immune System and Inflammatory Bowel Disease June 2007 December 2017
NCT00524537 Completed A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD) September 2007 December 2015
NCT00528073 Completed Phase 2 Placebo Controlled Study of 3 Doses of Rifaximin-EIR Tablet to Treat Moderate, Active Crohn's Disease September 2007 October 2009
NCT00543374 Completed Phase 3 Extended Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-Resistant Moderate-to-Severe Crohn's Disease September 17, 2007 April 28, 2011
NCT00546546 Completed Phase 4 Early Immunosuppressants in Crohn's Disease July 2005 June 2013
NCT00553176 Completed The Crohn's Therapy, Resource, Evaluation, and Assessment Tool Registry August 1999 May 2012
NCT00554710 Completed Phase 4 Top Down Versus Step Up Strategies in Crohn's Disease May 2001 January 2004
NCT00572780 Completed Can CT Enteroclysis Predict the Outcome of Crohn's Disease August 2007 January 2012
NCT00573469 Completed Phase 2 Efficacy and Safety Study of D9421-C 9 mg and 15 mg Versus Placebo in Japanese Patients With Active Crohn's Disease October 2006 March 2008
NCT00583232 Completed Phase 1 Protein and Energy Metabolism in Pediatric Crohn's Disease February 2006 December 2008
NCT00586352 Completed N/A Protein Metabolism in Newly Diagnosed Pediatric Inflammatory Bowel Disease January 2006 November 2011
NCT00586599 Completed N/A Levels of the Stat4 Alpha and Stat4 Beta Isoforms in PBMCs From Patients With Crohn's Disease and Ulcerative Colitis August 2007 July 2014
NCT00587041 Completed Phase 1/Phase 2 Use of Oral Probiotics to Reduce Urinary Oxalate Excretion February 2006 July 2009
NCT00588393 Completed Phase 2 FolateScan in Autoimmune Disease September 2006 December 2007
NCT00588653 Completed Phase 4 Diagnostic Accuracy of Capsule Endoscopy in Small Bowel Crohn's Disease January 2004 August 2004
NCT00596700 Completed Phase 3 Capsule Endoscopy Crohn's Disease Activity Index - Validation Multi Center Study January 2007 January 2012
NCT00603616 Completed Phase 2 Induction of Clinical Response Using Rifaximin in Crohn's Disease November 2008 November 3, 2020
NCT00609973 Completed Phase 2 Ciprofloxacin for the Prevention of Postoperative Endoscopic Recurrence in Crohn's Disease May 2008 December 2011
NCT00613197 Completed Phase 3 EPANOVA in Crohn's Disease, Study 1 January 2003 August 2006
NCT00615199 Completed Phase 2 A Study to Investigate the Safety and Efficacy of CP-690,550 in Patients With Moderate to Severe Crohn's Disease January 2008 October 2009
NCT00619489 Completed Phase 2 Long Term Safety of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease December 2007 March 2010
NCT00622557 Completed General Surgical Outcomes Quality Improvement Database (UH-SOCRATES) May 1, 2007 January 6, 2017
NCT00655135 Completed Phase 2 Phase 2 Study of the Safety and Efficacy of LDP-02 in Mildly to Moderately Active Crohn's Patients February 2000
NCT00655733 Completed Phase 2 Phase II Study of HMPL-004 in Subjects With Crohn's Disease April 2006 April 2009
NCT00663117 Completed Phase 2 The Effects of Naltrexone on Active Crohn's Disease September 2006 October 2009
NCT00676988 Completed Study to Determine Relationship Between Serum Infliximab and Efficacy in Luminal Crohn's Disease Patients May 2008 April 2011
NCT00679003 Completed N/A Managing Inflammatory Bowel Disease September 2007 March 2014
NCT00686374 Completed Phase 3 Efficacy and Long Term Safety of Adalimumab in Pediatric Subjects Who Have Demonstrated Clinical Response in M06-806 May 1, 2008 April 4, 2017
NCT00688636 Completed Phase 4 Infliximab for the Prevention of Recurrent Crohn's Disease After Surgery January 2005 January 2009
NCT00705614 Completed Postmarketing Safety Surveillance European Registry of Crohn's Disease Patients Treated With Remicade or Standard Therapy (MK-2155-035) July 2003 February 2013
NCT00711945 Completed Growth Relapse and Outcomes With Therapy 1 March 2008 December 2014
NCT00715117 Completed Phase 2 The Efficacy of Low Dose Naltrexone Therapy in Children With Crohn's Disease July 2008 August 2010
NCT00720538 Completed Phase 3 Thalidomide in Pediatric Inflammatory Bowel Diseases. August 2008 June 2012
NCT00723047 Completed Phase 3 Fibrin Glue for Perianal Fistulas in Crohn's Disease: a Randomized Controlled Trial November 2003 August 2006
NCT00723840 Completed Assessment of the Social Cost of Crohn's Disease: Economic and Quality of Life Aspects (Study P04560) September 2006 December 2009
NCT00724529 Completed Post Marketing Surveillance of Remicade June 2007 August 2011
NCT00724958 Completed Program Extension of Real Life Dosing of Remicade in Austria for Crohn's Disease (Study P04052)(COMPLETED) December 2004 July 2010
NCT00727298 Completed Post Marketing Surveillance Study of Remicade in Patients With Chronic Inflammatory Diseases (P04840) February 2006 August 2011
NCT00737932 Completed Phase 2 Laquinimod Phase IIa Study in Active Crohn's Disease May 2010 December 2011
NCT00739986 Completed Phase 2 Semapimod for Treatment of Moderate to Severe Crohn's Disease 1 or 3 Days' Treatment Versus Placebo October 2002 August 2004
NCT00740103 Completed Phase 2 Long-term Study of Semapimod (CNI-1493) for Treatment of Crohn's Disease December 2002 September 2004
NCT00741910 Completed Phase 2 Extension Study of Semapimod 60 mg IV x 3 Days July 2003 June 2006
NCT00769236 Completed N/A Evaluation of Intestinal Secretion of Antibodies and Auto-antibodies Associated With Crohn's Disease June 2008 August 2010
NCT00769353 Completed N/A Understanding and Treating Neuropsychiatric Symptoms of Pediatric Physical Illness January 2008 January 2014
NCT00771667 Completed Phase 2 A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously Treated With Anti-TNF Therapy December 2008 December 2010
NCT00780949 Completed N/A Immunological Consequences of CARD15/NOD2 Mutations in Crohn's Disease January 2009 January 2012
NCT00783692 Completed Phase 3 Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease December 2008 May 2012
NCT00790543 Completed Risk Stratification of Rapid Disease Progression in Children With Crohn's Disease November 2008 December 31, 2020
NCT00790933 Completed Phase 3 An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease May 22, 2009 October 31, 2017
NCT00791557 Completed N/A Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease October 2008 February 2010
NCT00798473 Completed Phase 3 Zoledronate for Osteopenia in Pediatric Crohn's September 2004 November 2008
NCT00805766 Completed Phase 3 Efficacy and Safety of Increased Dose of TA-650 (Infliximab) in Patients With Crohn's Disease (CD) December 2008 July 2010
NCT00808262 Completed Phase 1/Phase 2 Safety and Immunogenicity of a TNFa Kinoid in Patients With Crohn's Disease October 2008 December 2010
NCT00810030 Completed Phase 3 FERINJECT for Correction of Anaemia in IBD Patients, FER-IBD-COR October 2008 April 2010
NCT02791854 Enrolling by invitation Improving the Quality of Care for Adults With Inflammatory Bowel Disease February 26, 2016 December 2030
NCT04939337 Enrolling by invitation Phase 1 A Study of TH-SC01 for Treating Complex Perianal Fistula in Perianal Crohn's Disease. November 12, 2020 August 2024
NCT04456517 Enrolling by invitation Phase 2 Reduce Crohn's-Associated Diarrhea With Sodium Channel Therapy October 18, 2022 December 2025
NCT01510431 No longer available Safety and Treatment Outcome Study of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects With Treatment-resistant Crohn's Disease
NCT03914261 No longer available Expanded Access to Risankizumab
NCT06244849 Not yet recruiting N/A TOward a Better Understanding of the autoPhagy Machinery for the Identification of Potential Novel Biomarkers and Therapeutic Targets in Crohn's Disease - TOPIC Study June 1, 2024 January 1, 2026
NCT06430801 Not yet recruiting Phase 3 A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008) June 11, 2024 September 11, 2029
NCT04290156 Not yet recruiting N/A The Effect of Joint Transition Visits on Quality of Life in Inflammatory Bowel Diseases (TRANS-IBD) April 1, 2020 November 1, 2024
NCT06211400 Not yet recruiting N/A Vibration Exercise for Crohn's to Observe Response September 1, 2024 January 1, 2028
NCT06332534 Not yet recruiting Phase 3 Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease July 26, 2024 December 20, 2034
NCT06227910 Not yet recruiting Phase 3 A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease July 22, 2024 August 1, 2028
NCT06362863 Not yet recruiting N/A Evaluation of Enteral Nutrition Biscuits for Inducing Remission in Moderate-to-severe Crohn's Disease June 2024 December 2025
NCT05626023 Not yet recruiting Phase 1/Phase 2 A Study of Human TH-SC01 Cell Injection for Treating Perianal Fistulas in Patients With Crohn's Disease November 30, 2022 December 30, 2023
NCT06100289 Not yet recruiting Phase 3 A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease September 30, 2024 June 30, 2027
NCT06405087 Not yet recruiting Phase 3 A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD) December 2, 2024 January 26, 2032
NCT06459297 Not yet recruiting Study of Oral Upadacitinib to Assess Change in Disease Activity and Adverse Events in Adult Participants With Ulcerative Colitis or Crohn's Disease June 30, 2024 December 31, 2025
NCT06274554 Not yet recruiting Phase 3 Testing the Role for Anti-fungal Therapy in Improving the Response to Medicine for Crohn's Disease June 2024 December 2029
NCT06180382 Not yet recruiting Phase 4 Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration. June 2024 January 2027
NCT05078879 Recruiting Phase 1 Empagliflozin as a Treatment for Severe Congenital Neutropenia Due to G6PC3 Deficiency November 16, 2021 October 30, 2024
NCT04002180 Recruiting Specified Drug-Use Survey on Vedolizumab for IV Infusion 300 mg [Crohn's Disease] July 1, 2019 October 31, 2025
NCT05428345 Recruiting A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea September 25, 2023 November 30, 2027
NCT03992469 Recruiting Phase 1 Study to Evaluate Safety, Tolerability and Efficacy of Oral E-B-FAHF-2 in Mild-to-Moderate Crohn's Disease February 15, 2023 May 2025
NCT02839317 Recruiting COmparison of MicroBiota AccordIng to Age in Crohn's Disease (COMeBACk) May 9, 2016 May 2024
NCT04713631 Recruiting Phase 2 Safety and Efficacy of Artesunate & Curcumin in Crohn's Disease January 21, 2021 January 2024
NCT06124287 Recruiting MRE Predictors of Disease Relapse After Stopping Biologics February 27, 2024 February 2027
NCT01140789 Recruiting GWA Study in Patients With Inflammatory Bowel Disease April 2010 April 2037
NCT02636517 Recruiting Phase 1 Fecal Microbiome Transplant December 2015 December 2025
NCT04701411 Recruiting Phase 3 A Study of Darvadstrocel for Treating Complex Perianal Fistulas in Children and Teenagers With Crohn's Disease June 30, 2021 December 31, 2025
NCT05683730 Recruiting N/A Intermittent Caloric Restriction in Patients With Mild to Moderate Crohn's Disease April 18, 2023 August 1, 2027
NCT06045754 Recruiting Phase 4 A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease April 18, 2024 June 28, 2027
NCT06064864 Recruiting N/A Efficacy and Safety of Formulation Switching Between SC Infliximab and IV Infliximab in Patients With CD October 9, 2023 December 31, 2026
NCT05733845 Recruiting N/A Evaluation of Molecular Mechanisms of Non-response to Therapy in Patients With Inflammatory Bowel Disease June 14, 2023 August 1, 2030
NCT06063967 Recruiting Phase 3 A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. November 15, 2023 February 23, 2028
NCT06249555 Recruiting VOICE-Early Response to Vedolizumab and Ustekinumab in Participants With Crohn's Disease: A Prospective Observational Study March 20, 2024 September 2026
NCT06053424 Recruiting Phase 1 Positron Emission Tomography Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Healthy Participants and Patients With Crohn's Disease September 25, 2023 August 12, 2024
NCT03167437 Recruiting Phase 1/Phase 2 An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab October 30, 2017 June 30, 2026
NCT06351124 Recruiting Phase 1/Phase 2 Beta-Hydroxybutyrate Feasibility Treating IBD May 15, 2024 December 31, 2025
NCT04496063 Recruiting Phase 4 USTekinumab in Fistulising Perianal Crohn's Disease (USTAP) November 16, 2020 June 30, 2025
NCT05442567 Recruiting Phase 3 A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD) May 16, 2023 August 15, 2031
NCT06408935 Recruiting Phase 3 Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients April 17, 2024 August 30, 2028
NCT05836883 Recruiting Phase 1/Phase 2 Study of ExoFlo for the Treatment of Perianal Fistulas August 28, 2023 December 2024
NCT03251118 Recruiting A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease July 24, 2017 July 2025
NCT03256240 Recruiting N/A Study of the Kono-S Anastomosis Versus the Side-to-side Functional End Anastomosis March 12, 2014 December 31, 2033
NCT02580617 Recruiting Phase 1 A Study to Evaluate the Safety of ALLO-ASC-CD for Treatment of Crohn's Disease November 9, 2015 December 2023
NCT05837897 Recruiting Phase 3 A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease June 16, 2023 May 30, 2031
NCT00692939 Recruiting Phase 1/Phase 2 Autologous Stem Cell Transplantation for Crohn's Disease June 26, 2012 December 2026
NCT05841537 Recruiting An Observational Study to Assess Change in Disease Activity and Adverse Events In Adult Participants With Moderate to Severe Active Crohn's Disease (CD) June 9, 2023 January 31, 2028
NCT06233461 Recruiting Phase 2 A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease March 5, 2024 July 23, 2027
NCT06429241 Recruiting Phase 1 Evaluate the Distribution and Dynamic Behavior of TH-SC01 Cells in Vivo in Patients With Perianal Fistula April 8, 2024 December 2025
NCT05923073 Recruiting Phase 3 A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease March 13, 2024 April 27, 2028
NCT04232553 Recruiting Phase 3 A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease June 22, 2020 December 20, 2026
NCT05242471 Recruiting Phase 2 A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease July 22, 2022 March 27, 2029
NCT05930275 Recruiting Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice. February 19, 2024 September 30, 2028
NCT05995353 Recruiting Phase 3 A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease December 11, 2023 April 28, 2029
NCT05509777 Recruiting Phase 3 A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease March 13, 2024 October 10, 2027
NCT04173273 Recruiting Phase 3 A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease January 6, 2020 August 8, 2029
NCT06023030 Recruiting An Observational Study to Assess Change in Disease Activity and Adverse Events in Adolescent and Adult Participants With Moderate to Severe Active Crohn's Disease (CD) in Japan July 28, 2023 November 30, 2026
NCT04847739 Recruiting Phase 2 Seeded Cells on Matrix Plug Treating Crohn's Perianal Fistulas (STOMP-II) September 13, 2021 May 2026
NCT04844606 Recruiting Phase 3 A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON) May 26, 2021 July 30, 2030
NCT06407674 Recruiting Non-invasive Assessment of RECTUM (POUCH) by US (RECT-US) in a Cohort of IBD Patients January 10, 2024 May 28, 2025
NCT06226883 Recruiting Phase 2 A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease April 4, 2024 April 2028
NCT04777656 Recruiting Phase 3 Use of Crohn's Disease Exclusion Diet on Top of Standard Therapy Versus Standard Therapy Alone in Unstable Pediatric Crohn's Disease Patients. September 26, 2022 November 2026
NCT01797224 Recruiting OTIS Autoimmune Diseases in Pregnancy Project March 2012 October 2026
NCT04060303 Recruiting Phase 3 ENhanced Recovery in CHildren Undergoing Surgery July 1, 2020 December 31, 2024
NCT05113095 Recruiting A Survey of Darvadstrocel in People With Crohn's Disease November 30, 2021 December 31, 2029
NCT01731665 Recruiting Epidemiology of Inflammatory Bowel Disease in the Songpa-Kangdong District, Seoul, Korea. December 2012 June 2029
NCT05626088 Recruiting A Study in Adults With Inflammatory Bowel Disease (IBD) Receiving Vedolizumab in the Patient Support Program (PSP) in Brazil April 10, 2023 January 2, 2025
NCT04738942 Recruiting Phase 3 A Study of Intravenous Vedolizumab Administered Every 4 Weeks in Japanese Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease June 4, 2021 September 18, 2024
NCT03017014 Terminated A Study to Assess Safety and Effectiveness of Adalimumab for Treating Children and Adolescents With Crohn's Disease in Real Life Conditions September 26, 2017 October 14, 2019
NCT00360022 Terminated N/A Transition of Inflammatory Bowel Disease (IBD) Patients From Pediatric to Adult Gastroenterologist (GI) August 2006 February 2011
NCT00406653 Terminated Phase 3 A Study of Abatacept in Patients With Active Crohn's Disease December 2006 November 2009
NCT00130390 Terminated Phase 2 Study of Nitazoxanide Tablets in the Treatment of Mild to Moderate Active Crohn's Disease August 2005 July 2008
NCT02914600 Terminated Phase 3 Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease March 17, 2017 August 1, 2023
NCT00417690 Terminated Phase 2 High Dose Oral 4-Aminosalicylic Acid (PASER®) to Control Acute Flares of Mild to Moderate Crohn's Disease January 2007 October 2008
NCT02930564 Terminated N/A The Challenge Study: A Dietary Personalization Protocol for Patients With Crohn's Disease and Deep Remission January 2017 May 29, 2022
NCT01880307 Terminated Phase 4 Infliximab Top-down in Pediatric Crohn January 2013
NCT00495521 Terminated Phase 2 High Dose Oral 4-Aminosalicylic Acid (PASER®) to Control Acute Flares of Mild to Moderate Crohn's Disease in Children June 2007 October 2008
NCT01947036 Terminated T and B Cell Responses in Autoimmune Diseases January 2014 October 2015
NCT00304252 Terminated Phase 2 Safety and Efficacy of Treatment With Interferon Beta-1a Rebif® in Patients With Crohn's Disease November 2001 September 2003
NCT00278577 Terminated Phase 1 Hematopoietic Stem Cell Support in Patients With Severe Crohn's Disease April 2001 February 2012
NCT00562887 Terminated Phase 2 Dose Ranging Study Comparing the Efficacy, Safety and Pharmacokinetics of Intravenous Infusions of ABT-874 vs Placebo in Subjects With Active Crohn's Disease November 2007
NCT01960426 Terminated Phase 4 Evaluation of Health Costs and Resource Utilization April 2014 May 2015
NCT00584740 Terminated Phase 2 Efficacy, Safety and Tolerability of AIN457 in Moderate to Severe Active Crohn's Disease August 2008 August 2010
NCT01986127 Terminated Phase 3 Adalimumab Intralesional in Intestinal Strictures of Crohn's Disease Patients February 14, 2014 June 30, 2018
NCT05784129 Terminated Phase 3 A Study of Guselkumab for the Treatment of Participants With Crohn's Disease After Surgical Resection February 21, 2023 October 10, 2023
NCT00610207 Terminated N/A Treatment of Crohn's Fistula Using a Porcine Intestine Submucosa Graft March 2007 April 2010
NCT00271947 Terminated Phase 2 Crohn's Disease Stem Cell Transplantation April 2005 April 2013
NCT00621257 Terminated N/A Vitamin D Levels in Children With IBD January 2008 March 2011
NCT00707512 Terminated CD INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring June 30, 2008 May 28, 2015
NCT00349752 Terminated Phase 3 Corticosteroid Sparing Effect of Certolizumab in Crohn's Disease November 2006 July 2009
NCT00257699 Terminated Phase 2 Study of Antibiotics in the Treatment of Colonic Crohn's Disease May 2006 July 2008
NCT02164877 Terminated Phase 2 Effect of Soluble Dietary Fiber on Bacterial Translocation in Crohn's Disease June 2014 June 2017
NCT00252369 Terminated N/A Treatment of Perianal Crohn's Disease, Combining Medical and Surgical Treatment.
NCT03478956 Terminated Phase 1 A Phase I Study Of Etrolizumab Followed By Open-Label Extension And Safety Monitoring In Pediatric Patients With Moderate To Severe Ulcerative Colitis Or Moderate To Severe Crohn's Disease March 27, 2018 September 27, 2023
NCT00752622 Terminated Phase 4 Treatment With Infliximab in a Medical Setting (Study P05587) November 2008 June 2010
NCT00755937 Terminated Remicade® Crohn's Disease Registry Across Canada (Study P02793) February 2002 September 2007
NCT03559517 Terminated Phase 3 Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 305) August 29, 2018 October 8, 2020
NCT00245505 Terminated Phase 3 The Effect on Mucosal Healing With Pentasa Sachet in Mild to Moderate Active "Drug: Crohn's Disease" February 2009 July 2009
NCT02193750 Terminated N/A Assessing the Tolerability of Oligosaccharide Supplementation in Patients With Crohn's Disease August 2015 September 2020
NCT03566407 Terminated N/A Blood and Stool Molecular Biomarkers Longitudinal Detection Study in Crohn's Disease (CD) Patients May 4, 2018 March 29, 2019
NCT03566823 Terminated Phase 3 Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 306) July 17, 2018 August 18, 2020
NCT03599622 Terminated Phase 2 An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's Disease July 16, 2018 October 23, 2023
NCT00792740 Terminated Phase 1/Phase 2 Effect of ITF2357 on Mucosal Healing in Patients With Moderate-to-severe Active Crohn's Disease October 22, 2007 March 11, 2009
NCT00796250 Terminated Phase 3 Efficacy of Infliximab in the Treatment of Patients Affected by Corticodependent Crohn's Disease (P02732) November 1, 2003 January 1, 2005
NCT02208310 Terminated Phase 4 Trial of High Dose Vitamin D in Patient's With Crohn's Disease April 2015 April 2016
NCT03627091 Terminated Phase 3 Efficacy and Safety Study of Ontamalimab as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307) February 6, 2019 September 13, 2021
NCT03635112 Terminated Phase 2 Efficacy and Safety of TD-1473 in Crohn's Disease November 19, 2018 December 30, 2021
NCT02240108 Terminated Phase 3 One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease October 28, 2014 October 6, 2017
NCT02240121 Terminated Phase 3 One Year Study of Rifaximin Delayed Release (DR) Tablets in Crohn's Disease August 21, 2014 August 16, 2017
NCT00899678 Terminated Phase 2 The Use of Certolizumab Pegol for Treatment of Active Crohn's Disease in Children and Adolescents April 2009 July 2012
NCT03650413 Terminated Phase 2 An Extension Study to Evaluate the Long-Term Safety and Tolerability of UTTR1147A in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease January 14, 2019 July 12, 2022
NCT00936585 Terminated N/A NIH Substudy of AIN457 (Anti-IL-17 Monoclonal Antibody) for Treatment of Moderate to Severe Crohn's Disease July 2009 February 2011
NCT00113503 Terminated Phase 2 Imuran Dosing in Crohn's Disease Study July 2005 December 2007
NCT00968721 Terminated Decisional Influences and Inflammatory Bowel Disease (IBD) Patients' Medication Use June 2010 December 2011
NCT00979485 Terminated Microparticles in Pediatric Inflammatory Disease August 2009 May 2011
NCT02272868 Terminated Phase 1/Phase 2 Fecal Microbial Transplant in Pediatric Crohn's Disease January 2015 October 1, 2016
NCT01009281 Terminated Phase 2 An Open Label Safety and Tolerability Study of AIN457 in Patients With Moderate to Severe Crohn's Disease October 30, 2009 August 19, 2010
NCT01012570 Terminated The Effect of Adalimumab on the Bone Microstructure in Crohn's Disease (CD) Patients August 2009
NCT01012726 Terminated N/A Study About the Effect of Doxycycline and Acetylcystein in the Treatment of CD-associated Fistulae November 2009 July 2012
NCT03759288 Terminated Phase 2/Phase 3 An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease December 7, 2018 October 18, 2023
NCT01046773 Terminated Phase 1 Vitamin D Supplementation as Non-toxic Immunomodulation in Children With Crohn's Disease January 2010 May 2017
NCT02324699 Terminated Phase 4 Corticosteroids With Vedolizumab in Crohn's Disease April 2016 February 8, 2018
NCT02326155 Terminated To Evaluate the Safety and Efficacy of Remsima™ in Patients With Crohn's Disease (CD) or Ulcerative Colitis (UC) December 8, 2014 February 28, 2020
NCT01074580 Terminated Contrast Enhanced Ultrasonography (CEUS) of Patients With Crohn's Disease November 2009 December 2013
NCT02341755 Terminated Dual Energy Computerized Tomography (DE-CT) in Patients With Crohn's Disease May 2012 November 2014
NCT03833596 Terminated Phase 4 Exclusive Enteral Nutrition and Corticosteroids Therapy in Crohn's Disease (EENCD) October 25, 2018 November 1, 2019
NCT01094613 Terminated Phase 1/Phase 2 Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease November 2010 December 2012
NCT03850509 Terminated Phase 2 Efficacy and Safety of Oral OPS-2071 in Participants With Crohn's Disease Showing Symptoms of Active Inflammation February 25, 2020 May 22, 2020
NCT01150890 Terminated Phase 2 Brodalumab (AMG 827) in Adults With Moderate to Severe Crohn's Disease November 9, 2010 October 15, 2011
NCT03870334 Terminated Phase 2 Efficacy and Safety of Oral BT-11 in Moderate to Severe Crohn's Disease May 5, 2021 August 26, 2022
NCT02392286 Terminated Phase 4 Corticosteroid Dosage for Crohn's Disease Flare March 2015 December 19, 2016
NCT01182467 Terminated Use of PET-CT in the Management of Crohn's Disease February 2011 September 2013
NCT02405442 Terminated Phase 2 Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease April 30, 2015 December 22, 2016
NCT01190839 Terminated Phase 3 A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence November 2010 December 2014
NCT01199302 Terminated Phase 2 Long-term Safety Study of Brodalumab in Adults With Crohn's Disease February 2, 2011 October 18, 2011
NCT00329537 Terminated Phase 2 Study of Sargramostim in Moderately to Severely Active Crohn's Disease June 2006 May 2007
NCT02413047 Terminated N/A Evaluate if Response to Infliximab or Adalimumab May be Regained With an Immunomodulator May 2015 February 2018
NCT02417974 Terminated Phase 2 Prevention of Recurrence of Crohn's Disease by Fecal Microbiota Therapy (FMT) September 2015 February 4, 2021
NCT01277289 Terminated Phase 3 Intra-erythrocyte Dexamethasone Versus Placebo in Patients With Steroid-dependent Crohn's Disease June 3, 2009 June 2012
NCT01288053 Terminated Phase 1/Phase 2 Non-myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (NST) for Patients With Refractory Crohn's Disease January 2010 June 2016
NCT03961815 Terminated Phase 3 Open-label Extension Study of Brazikumab in Crohn's Disease January 6, 2020 September 19, 2023
NCT02481687 Terminated The Value of I-Scan and Confocal Laser Endomicroscopy for the Assessment of Chronic Inflammatory Bowel Disease June 2015 June 2017
NCT01316939 Terminated Phase 3 GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease May 9, 2011 October 23, 2013
NCT01318993 Terminated Phase 3 Open-Label Extension Study of GSK1605786A April 1, 2011 October 29, 2013
NCT02574637 Terminated Phase 2 Evaluation of Efficacy and Safety of Brazikumab (MEDI2070) in Participants With Active, Moderate to Severe Crohn's Disease January 5, 2016 January 29, 2018
NCT01388933 Terminated Phase 2 A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease September 2011 September 2013
NCT00307931 Terminated Phase 3 Certolizumab Pegol for Treatment of Adult Greek Patients With Moderate to Severe Crohn's Disease Who Failed Infliximab April 2007 August 2008
NCT01438151 Terminated N/A Understanding the Relationship Between Infliximab Levels to Clinical Response of Remicade in Crohn's Disease December 2011 December 2013
NCT02622763 Terminated Phase 1 Intralesional Tolerogenic Dendritic Cells in Crohn's Disease Treatment November 2015 May 5, 2019
NCT02641171 Terminated Volatiles in Exhaled Breath and Blood in Crohn's Disease: Validation Cohort December 2015 October 4, 2016
NCT02641392 Terminated Phase 3 A Long-term Active Treatment Study of Mongersen (GED-0301) in Subjects With Crohn's Disease July 25, 2016 January 4, 2018
NCT02649075 Terminated N/A To Evaluate SBI in the Dietary Management of Mild to Moderate Crohn's Disease February 2016 August 2017
NCT02685683 Terminated Phase 2 Pharmacodynamic and Clinical Outcome Study of Mongersen in Patients With Crohn's Disease April 4, 2016 November 9, 2017
NCT01536418 Terminated Phase 3 An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease November 11, 2011 October 17, 2013
NCT01540292 Terminated Phase 1/Phase 2 Mesenchymal Stem Cell Therapy for the Treatment of Severe or Refractory Inflammatory and/or Autoimmune Disorders February 1, 2013 December 31, 2015
NCT04804046 Terminated N/A Synbiotics and Post-op Crohn's Disease July 15, 2021 December 31, 2023
NCT01545050 Terminated Phase 2 Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease June 2012 December 2013
NCT01562951 Terminated Phase 3 Assessment of Mucosal Activity to Improve the Prognosis of Patients With Crohn's Disease Treated With Immunosuppressants October 2012 March 2014
NCT01569503 Terminated Phase 3 Vagus Nerve Stimulation a New Approach in the Treatment of Crohn's Disease March 2012 May 30, 2017
NCT01577264 Terminated Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD) August 2011 October 2015
NCT04995783 Terminated Predicting Medication Response for Autoimmune Disease September 1, 2020 August 1, 2022
NCT02793778 Terminated Phase 2 Efficacy of CROWN in Repair and Maintenance of the Intestinal Mucosa in Patients With CD Receiving Anti-TNF Therapy July 2016 June 1, 2018
NCT05049525 Terminated Phase 2 Evaluation of the Response of Itraconazole and Terbinafine Therapy in Subjects With Crohn's Disease February 22, 2022 February 28, 2024
NCT01696942 Terminated Phase 4 Cimzia Versus Mesalamine for Crohn's Recurrence February 2013 June 2016
NCT05068284 Terminated Phase 2 A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohn's Disease January 31, 2022 July 20, 2023
NCT00098111 Terminated Phase 3 Imuran (Azathioprine) Dose-Ranging Study in Crohn's Disease April 2005 July 2007
NCT00177866 Terminated Phase 4 Safety of Celecoxib in Patients With Crohn's Disease December 2003 June 2010
NCT01759017 Terminated PET/CT to Predict Response to Infliximab Therapy in Patients With Crohn's Disease December 2012 January 2015
NCT02882841 Terminated N/A MOlecular BIomarkers and Adherent and Invasive Escherichia Coli (AIEC) Detection Study In Crohn's Disease Patients September 2016 December 2017
NCT01802593 Terminated Phase 4 Comparison of 2 Immunomodulator Withdrawal Schemes for Infliximab Monotherapy in Active Pediatric Crohn's Disease After Thiopurine Failure February 2013 December 2015
NCT00152841 Terminated Phase 2 Effect of Iron and Vitamin E Supplementation on Disease Activity in Patients With Either Crohn's Disease or Ulcerative Colitis June 2002
NCT01817972 Unknown status Phase 3 Cimzia Versus Cimzia Plus Azathioprine in the Treatment of Active Crohn's Disease March 2013 November 2014
NCT00510978 Unknown status Phase 2/Phase 3 Probiotics in GastroIntestinal Disorders January 2002 November 2007
NCT02330458 Unknown status The Role of Small Bowel Ultrasound in Initiation of Infliximab in Crohn's Disease Patients July 2014 May 2018
NCT01820247 Unknown status N/A Efficacy Study of Tripterygium Glycoside Combined With Enteral Nutrition in the Treatment of Crohn's Disease for Induction Remission December 2012 September 2013
NCT01078935 Unknown status Phase 4 The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation, Endothelial Function, and Markers of Inflammation December 2012
NCT02335281 Unknown status Phase 2 Standardized Fecal Microbiota Transplantation for Inflammatory Bowel Disease January 2015 December 2017
NCT01887548 Unknown status N/A Personality Traits and Its Impact on Quality of Life and Clinical Outcome Evaluation in Crohn's Patients March 2012 December 2013
NCT00731809 Unknown status Phase 4 Evaluation of PET CT in the Management of Patients With Crohn's Disease. April 2008 October 2010
NCT02760836 Unknown status Predictive Model of Clinical Outcomes Using Web-based Self-reporting Symptom Diary for Crohn's Disease April 2016 December 2020
NCT01765998 Unknown status Phase 4 The Effect of Probiotics on Exacerbation of Inflammatory Bowel Disease Exacerbation (Crohn's Disease) February 2013 February 2014
NCT03698500 Unknown status N/A Specific microRNAs as Potential Biomarker for Inflammatory Bowel Disease January 2017 December 2020
NCT00353756 Unknown status Phase 1 Phase 1 Study of Safety and Biological Effects of C326, an Inhibitor of IL-6, in Crohn's Disease September 2006 September 2007
NCT01144156 Unknown status N/A Small Bowel Mucosal Healing Induced by Adalimumab in Crohn's Disease Patients as Assessed by Capsule Endoscopy
NCT02383953 Unknown status SSAT 054: Non Genetic Factors in the Pathogenesis of IBD in Twins May 2015 October 2017
NCT01622270 Unknown status Energy Expenditure in Patients With Crohn's Disease June 2012
NCT02940054 Unknown status RED-FLAGS Index Validation in Crohn's Disease Patients February 2015 March 2018
NCT01632462 Unknown status Phase 4 A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease September 2012 February 2015
NCT00265772 Unknown status Phase 4 Comparison of a Nutritional Anti-Inflammatory Treatment to Steroids for Pediatric Crohn's Disease - the Molecular Basis November 2005 April 2008
NCT02395354 Unknown status N/A Comparative Prospective Multicenter Randomized Study of Endoscopic Treatment of Stenosis in Crohn´s Disease September 2013 December 31, 2018
NCT01705522 Unknown status Multimodal Approach in IBD Patients October 2012 October 2019
NCT00599625 Unknown status N/A Pravastatin Therapy in Patients With Active Crohn's Disease: A Pilot Study October 2004 December 2011
NCT02000362 Unknown status Phase 1/Phase 2 Safety and Efficacy of FURESTEM-CD Inj. in Patients With Moderately Active Crohn's Disease(CD) August 2014 October 2018
NCT02777034 Unknown status N/A Laparoscopy Combined With Enhanced Recovery Pathway May 2016 December 2017
NCT01881464 Unknown status Anti TNF α Improves Endothelial Dysfunction in IBD Patients May 2014 June 2018
NCT00275418 Unknown status Phase 3 Beta Carotene From Natural Source for Patients With Non-Active Crohn's Disease July 2002
NCT01231217 Unknown status N/A Green Tea in Crohn's Disease October 2010
NCT00886327 Unknown status Detecting Postoperative Recurrence in Crohn's Disease May 2009 December 2013
NCT00851565 Unknown status Phase 4 Use of Combined Measurements of Serum Infliximab and Anti-infliximab Antibodies in the Treatment of Patients With Crohns Disease Failing Infliximab Therapy June 2009 February 2014
NCT02245594 Unknown status GI Symptoms and Sleep Disturbances in Patients With Quiescent Crohns Disease October 2014 October 2015
NCT01244386 Unknown status Low-dose CT Using Iterative Reconstruction in Patients With Inflammatory Bowel Disease June 2010 December 2011
NCT00367705 Unknown status Phase 4 VSL#3 Treatment in Children With Crohn's Disease August 2009 December 2010
NCT03648398 Unknown status N/A Pilot Study of an Online Therapeutic Education Program for Patients With Inflammatory Bowel Disease January 29, 2021 April 1, 2023
NCT02450513 Unknown status Adalimumab Trough Concentrations in Crohn's Disease: A Pilot Pharmacokinetic Study March 2012
NCT01266629 Unknown status The Clinical Utility of Fecal Caprotectin and Lactoferrin in Patients Undergoing Capsular Endoscopy December 2010 September 2011
NCT02852694 Unknown status Phase 4 Reduce Risk for Crohn's Disease Patients February 28, 2017 July 2022
NCT02858557 Unknown status N/A The Effect of Diet on Microbial Profile and Disease Outcomes in Patients With Inflammatory Bowel Diseases September 2016 September 2018
NCT02452151 Unknown status Phase 4 "Efficacy and Safety of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission: the SIMILAR Trial" August 2015 September 2016
NCT03524144 Unknown status N/A Upper Gastrointestinal Lesions in Crohn's Disease June 1, 2017 May 30, 2018
NCT02453607 Unknown status The Impact of 6MP Metabolite Levels on Infliximab Pharmacokinetics and Anti-infliximab Antibodies in Crohn's Disease November 17, 2014 June 30, 2020
NCT02465944 Unknown status Phase 1/Phase 2 A Pilot Study of FFP104 in Subjects With Crohn's Disease January 2016 December 2017
NCT01823042 Unknown status N/A The Efficacy of Enteral Nutrition in Fill of the Treatment Blank Period of the Postoperative Maintain Remission Medication for Crohn's Disease (CD) October 2012 July 2013
NCT04276636 Unknown status Early Phase 1 Exploring the Effects of Caltrate Supplement on the Chronic Course of Crohn's Disease Patients With Vitamin D Deficiency October 2020 March 2021
NCT02825316 Unknown status N/A Mediterranean Diet as an add-on Therapy for Induction of Remission in Patients With Active Crohn's Disease July 2016 January 2019
NCT01503099 Unknown status Intestinal Tuberculosis Diagnostics and the Differentiation From Crohn's Disease October 2009 December 2012
NCT02066272 Unknown status Safety of Anti-tumor Necrosis Factor (TNF) Monoclonal Antibodies in Inflammatory Bowel Disease January 2014 December 2016
NCT03056664 Unknown status Phase 2/Phase 3 The Role of MSC in the Treatment of Fistulas in Patients With Perianal Crohn's Disease January 2017 December 2019
NCT02532738 Unknown status Phase 2/Phase 3 The Efficiency of MSC in Refractory Crohn's Disease January 2016 December 2018
NCT02578576 Unknown status The Diagnostic Methods of Early Postoperative Flare-up of Crohn's Disease December 2015
NCT03257345 Unknown status VEST: The UK Vedolizumab Real Life Experience Study in Inflammatory Bowel Disease February 3, 2017 December 31, 2019
NCT02193802 Unknown status N/A Role of Capsule Endoscopy in the Evaluation of Mucosal Changes During Treatment of Patients With Active Crohn's Disease May 2014 March 2022
NCT01735461 Unknown status N/A Calcium Supplements Strategy for Kidney Stones Prevention in Crohn's Patients December 2012 December 2023
NCT02597829 Unknown status Phase 4 Does Clinical Response Correlate With Serum Certolizumab Levels? November 2015 October 2018
NCT02926300 Unknown status Long-term Safety and Efficacy of FURESTEM-CD Inj. in Patients With Moderately Active Crohn's Disease(CD) November 2015 November 2021
NCT01874015 Unknown status Phase 1 Transplantation of Bone Marrow Mesenchymal Stem Cell in Crohn's Disease February 2013 February 2018
NCT02716454 Unknown status N/A Early Surgery Versus Conservative Treatment in Patients With Ileocaecal Crohn's Disease May 2016 December 2021
NCT02867540 Unknown status N/A Comparison of Endoscopy and Diffusion-weighted Enterography-MRI for the Diagnosis of Crohn's Disease Recurrence Following Ileocolic Resection: a Pilot Study November 2014 May 2017
NCT04308850 Unknown status Early Phase 1 Exploring the Effects of Vitamin D Supplementation on the Chronic Course of Patients With Crohn's Disease With Vitamin D Deficiency October 2020 April 2021
NCT02311660 Unknown status N/A Vagus Nerve Stimulation in Crohn's Disease December 2014 December 2017
NCT01548014 Unknown status Phase 3 The Effect of a Probiotic Preparation (VSL#3) Plus Infliximab in Children With Crohn's Disease January 2010 January 2016
NCT01554007 Unknown status Clinical Course of Korean Crohn's Disease Cohort December 2012 December 2019
NCT00224562 Unknown status The RATIO: Registry of Infections and Lymphoma in Patients Treated With TNF-a Antagonists February 2004
NCT01015391 Unknown status N/A Efficacy Study of T2 Versus AZA to Maintain Clinical and Endoscopic Remission in Postoperative Crohn's Disease November 2009 June 2013
NCT03729674 Unknown status Comparative Effectiveness and Safety of Biosimilar and Legacy Drugs November 26, 2018 December 31, 2022
NCT01024647 Unknown status Phase 4 Optimizing Cimzia in Crohn's Patients December 2009 May 2013
NCT02044952 Unknown status Phase 2/Phase 3 Efficacy and Safety Study of Tripterygium Glycoside in the Treatment of Crohn's Disease for Induction Remission January 2014 July 2016
NCT00745329 Unknown status The Effect of Infliximab on Sperm Quality October 2008
NCT03815851 Unknown status N/A Relationship Between Prophylactic Drainage and Postoperative Complications (PPOI) in Crohn's Patients After Surgery September 6, 2016 December 31, 2022
NCT01040910 Unknown status Phase 1/Phase 2 Cannabis for Inflammatory Bowel Disease January 2010 July 2012
NCT02874495 Unknown status Anticipation Effect on Painful Phenomenons Linked to Rectal Distension for Patients With a Crohn's Disease in Remission January 2012 April 2017
NCT00178438 Withdrawn Phase 1/Phase 2 Wireless Capsule Endoscopy in Small-Bowel Crohn's Disease June 2005 June 2006
NCT02225795 Withdrawn N/A Pilot Study of Stem Cell Transplantation for Children and Young Adults With Refractory Crohn's Disease. August 2014 December 2019
NCT00801125 Withdrawn Phase 4 Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-α Therapy December 2008
NCT04073472 Withdrawn Phase 1 Mesenchymal Stem Cells for the Treatment of Pouch Fistulas in Crohn's June 1, 2021 June 1, 2023
NCT00783575 Withdrawn Genetic Markers as Predictors of Phenotypes in Pediatric Onset Crohn's Disease October 2002 January 2015
NCT05057273 Withdrawn Phase 2 Safety and Efficacy of Oral BT-11 in Crohn's Disease Patients With Moderate to Severe Disease November 2021 February 2022
NCT02834754 Withdrawn Phase 2 Vedolizumab Post Op Study December 1, 2018 May 1, 2019
NCT04151225 Withdrawn Phase 2 Study to Evaluate Safety, Tolerability and Efficacy of GSK2330811 in Crohn's Disease April 5, 2021 May 26, 2025
NCT04154735 Withdrawn Phase 2 Autologous Transplant Targeted Against Crohn's November 2019 March 2024
NCT02087878 Withdrawn A Blood and Tissue Sample Collection Study of Patients Who Have Inflammatory Bowel Disease, Who Have Been Treated With Adalimumab and Who Developed Hepatosplenic T-Cell Lymphoma March 31, 2014 September 30, 2019
NCT00376649 Withdrawn N/A Development of Workshop for Lifestyle Changing for Crohn's Disease Patients and Its Affect on the Disease's Indexes January 2007 December 2009
NCT00672763 Withdrawn Phase 4 Adjuvant Vitamin D With Corticosteroids in Active Crohn's Disease May 2008 May 2010
NCT02061163 Withdrawn Phase 1/Phase 2 Contrast-Enhanced Ultrasound in Human Crohn's Disease February 2015 January 2018
NCT04530877 Withdrawn Phase 4 Exclusive Enteral Nutrition vs. Infliximab in Chinese CD Patients October 1, 2022 September 30, 2024
NCT01433432 Withdrawn Phase 2 Open Label Extension Study to Protocol C2/13/DR-6MP-02 October 2011 August 2012
NCT04643483 Withdrawn Phase 3 A Study to Test Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Crohn's Disease June 2021 April 2026
NCT02676622 Withdrawn Phase 2 Autologous Stem Cell Transplant for Refractory Crohn's Disease April 2013 April 2013
NCT02677350 Withdrawn Phase 1 AlloGeneic Human Mesenchymal Stem Cells (hMSC) in PAtients With FistuLizing Crohn's Disease Via PErifistula iNjEctions (GALENE) December 1, 2019 December 2026
NCT05652491 Withdrawn The Role of Gut Microbiome in Predicting Comorbidities and Complications in Children With Inflammatory Bowel Disease December 9, 2022 May 30, 2023
NCT00358683 Withdrawn Phase 3 A Trial Evaluating Safety of Chronic Therapy With Certolizumab Pegol in Crohn's Disease November 2007
NCT01836289 Withdrawn Phase 1/Phase 2 High-dose Cyclophosphamide for Severe Refractory Crohn Disease March 2015 March 2018
NCT01523106 Withdrawn N/A L-carnitine to Treat Fatigue Associated With Crohn's Disease August 2013 February 2014
NCT01524120 Withdrawn Endoscopy and Endomicroscopy for Assessment of Mucosal Healing in Inflammatory Bowel Disease (IBD) April 2012
NCT01932658 Withdrawn Early Phase 1 Autologous Hematopoietic Stem Cell Transplantation for Crohn's Disease Treatment February 2014 March 2017
NCT02913508 Withdrawn Phase 2 Vedolizumab Subcutaneous (SC) Versus Intravenous (IV) in Ulcerative Colitis or Crohn's Disease April 2014 December 2015
NCT01293656 Withdrawn Study of Participants With Crohn's Disease and Ulcerative Colitis in Eastern Europe, Middle East, and North Africa (P08166) August 2011 July 2012
NCT05578508 Withdrawn Phase 1 Stem Cells for the Treatment of Pouchitis April 2022 February 2024
NCT00972218 Withdrawn Phase 4 Effectiveness and Safety of Spondylitis Related to Inflammatory Bowel Disease July 2009 January 2010
NCT00513552 Withdrawn Phase 4 Treatment of Crohn's Disease With an Antibiotic Regimen Directed Against Mycobacterium Avium Paratuberculosis July 2007 July 2007
NCT01897090 Withdrawn N/A A Crohn's Disease Diet to Reduce Symptoms of Crohn's Disease January 2013 January 2014
NCT01810185 Withdrawn Phase 2 Low Dose Naltrexone in Symptomatic Inflammatory Bowel Disease March 2013 March 2014
NCT02249078 Withdrawn Phase 1 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of 3 Subcutaneous and 1 Intravenous Dose of E6011 in Subjects With Active Crohn's Disease December 2014 April 2016
NCT02769494 Withdrawn Phase 3 The Efficacy of Topical Mesalazine Sustained-Release Tablets in Crohn's Disease Patients With Oral Ulcer March 2016 January 2017
NCT01635543 Withdrawn Investigation of Sexual Function in Crohn's Disease Patients With Perianal Fistulas October 2011 October 2013
NCT01635621 Withdrawn Phase 2 A Phase II Study to Assess the Efficacy and Safety of Olokizumab in Patients With Crohn's Disease June 2012 August 2013
NCT01647412 Withdrawn Phase 2 Growth Hormone and Exclusion Diet Therapy in Juvenile Crohn's Disease March 2012
NCT05028946 Withdrawn Phase 1 A Study of Oral Foralumab in Participants With Moderate to Severely Active Crohn's Disease May 1, 2022 November 7, 2023
NCT01876264 Withdrawn N/A Crohn's Extent of Resection Trial June 2013 June 2013
NCT01245088 Withdrawn Phase 1/Phase 2 Chondroitin Sulfate for Crohn's Disease January 2011 May 2012
NCT01266785 Withdrawn N/A Infliximab, Regulatory T Cells, IL2 and Crohn's Disease December 2010 July 2012
NCT00815061 Withdrawn Epidemiology of Ulcerative Colitis and Crohn's Disease in Non Jewish Israel Population July 2008 December 2016
NCT01674413 Withdrawn Phase 3 Calprotectin-Directed Humira® Maintenance Therapy (CADHUM) October 2013 March 2016
NCT01787786 Withdrawn Improving Treatment of Inflammatory Bowel Diseases Through Better Understanding Infliximab Drug and Antibody Levels September 2017
Disase is a (Disease Ontology)
DOID:0050589
Cross Reference ID (Disease Ontology)
EFO:0000384
Cross Reference ID (Disease Ontology)
GARD:10232
Cross Reference ID (Disease Ontology)
ICD10CM:K50.1
Cross Reference ID (Disease Ontology)
ICD9CM:555.1
Cross Reference ID (Disease Ontology)
MESH:D003424
Cross Reference ID (Disease Ontology)
NCI:C37262
Cross Reference ID (Disease Ontology)
SNOMEDCT_US_2023_03_01:7620006
Cross Reference ID (Disease Ontology)
UMLS_CUI:C0156147
Exact Synonym (Disease Ontology)
Crohn disease
Exact Synonym (Disease Ontology)
Crohn's disease of colon
Exact Synonym (Disease Ontology)
Crohn's disease of large bowel
Exact Synonym (Disease Ontology)
Granulomatous Colitis
Exact Synonym (Disease Ontology)
Pediatric Crohn's disease
HPO Human Phenotype ID (Human Phenotype Ontology)
HP:0100280